Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 8, Issue 2, Pages 85-92Publisher
ELSEVIER SCI LTD
DOI: 10.1046/j.1469-0691.2002.00347.x
Keywords
viridans streptococci; clarithromycin; azithromycin; macrolide resistance genes
Categories
Ask authors/readers for more resources
Objective To study the emergence of macrolide resistance in throat flora following treatment with clarithromycin or azithromycin. Methods Throat samples were collected before and after treatment and plated as a lawn on Columbia blood agar with an erythromycin E test strip. Minimum inhibitory concentrations (MICs) of erythromycin, clarithromycin and azithromycin were determined against isolates of distinct morphology with erythromycin E test MIC results equal to or greater than 2 mg/L. Polymerase chain reaction techniques were used to determine the genetic mechanisms of resistance. Results There were 749 resistant isolates of which 474 (63%) were streptococci. Only a quarter of the patients had no resistant streptococci before treatment started. There were increases in the numbers of resistant isolates and in the number of patients carrying a resistant flora during and after treatment. The most common genes identified were mef A/E in isolates with low-level resistance and erm A/M in isolates with high-level resistance. Conclusions There is a pool of streptococci carrying genes associated with macrolide resistance in the normal respiratory flora of generally healthy adults. Differences between the patients treated with clarithromycin and those treated with azithromycin were difficult to assess because of the large number of patients in each group with macrolide-resistant streptococci before treatment. Although there were some differences these were not statistically significant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available